Clinical Trials
13 trialsNCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00942877 2025-03-03
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00053794 2023-08-04
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00464620 2018-11-23
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00401388 2018-03-07
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
AEterna Zentaris
Phase 2 Completed
NCT00112463 2017-06-14
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00474994 2016-01-20
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00526149 2013-10-07
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00557609 2013-02-08
Phase 2 Study in Patients With MiT Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT00003939 2012-09-24
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed